Skip to main content

Table 1 Baseline characteristics of the study cohort at the time of recruitment

From: Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD

Characteristic n = 127
Age (years) 66.8 ± 8.6
Male sex, n (%) 68 (53.5)
Body mass index (kg/m2) 27.7 (5.5)
Smoking status (n, %)
 Current smoker 54 (43.0)
 Ex-smoker 73 (57.0)
Smoking history pack-yearsa 47.0 (26.3)
Post-bronchodilator FEV1 (% predicted) 46.4 ± 15.2
FEV1 (Litres) 1.20 ± 0.47
FVC (Litres) 2.82 ± 0.82
GOLD Stage, n (%)
 II (moderate) 57 (44.9)
 III (severe) 51 (40.2)
 IV (very severe) 19 (15.0)
Bronchiectasis evident on enrolment HRCT, n (%) 10 (7.9)
Frequency of exacerbation reporting in the preceding 12 months, n (%)
 1 exacerbation 28 (22.0)
 2 exacerbations 37 (29.1)
 3 or more exacerbations 62 (48.8)
Number of exacerbations in the preceding 12 months 3.1 ± 2.3
ICS use, n (%) 113 (89.0)
LABA use, n (%) 104 (81.9)
LAMA use, n (%) 93 (73.2)
Influenza vaccination in the preceding 12 months, n (%) 114 (89.8)
Pneumococcal vaccination in the preceding 12 months, n (%) 12 (9.4)
  1. Data presented as mean ± standard deviation or n (%) unless otherwise stated
  2. apresented as median (IQR)
  3. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, HRCT high resolution CT, ICS inhaled corticosteroid, LABA long acting beta agonist, LAMA long acting muscarinic antagonist